Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 12/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834231 | 0.85 | LIPE (0.74) | LIPESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4663484 | 0.85 | LIPE (0.74) | LIPESMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL7550305 | 0.84 | LIPE (1.00) | LIPESMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL10757188 | 0.84 | LIPE (0.73) | LIPESMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL12883888 | 0.82 | LIPE (0.70) | LIPESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1179999 | 0.80 | LIPE (0.67) | LIPEMEN1KMT2A | |
| SCHEMBL11832873 | 0.76 | SMN1; SMN2 (0.62) | LIPESMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL7557024 | 0.73 | LIPE (1.00) | LIPEMEN1KMT2A | |
| SCHEMBL14312997 | 0.72 | LIPE (0.55) | LIPESMN1; SMN2KMT2A | |
| SCHEMBL5649616 | 0.71 | CYP1A2 (0.59) | LIPESMN1; SMN2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | claimed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | LIPE 109/4885SMN1; SMN2 477/4885MEN1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.